New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesugen vs Argireline

Vesugen vs Argireline

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesugen
Skin & Cosmetic
Argireline
Summary
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
Argireline is the most widely researched topical 'Botox-alternative' cosmetic peptide, an acetylated hexapeptide that inhibits neuromuscular transmission to relax facial muscles and reduce dynamic wrinkle depth by 17–27% in clinical studies.
Half-Life
Short (minutes); sustained gene-regulatory effects
N/A — topical application; effect duration linked to formulation contact time
Admin Route
SubQ, Oral
Topical
Research
Typical Dose
10 mg per day
5–10% concentration
Frequency
Daily for 10–30 days
Twice daily
Key Benefits
  • Supports vascular endothelial cell function and integrity
  • May reduce endothelial inflammation and dysfunction
  • Anti-aging effects on blood vessel walls
  • Potential benefits in early atherosclerosis and vascular aging
  • Supports nitric oxide-mediated vascular tone
  • Reduces endothelial apoptosis from oxidative stress
  • Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
  • Reduces depth of dynamic expression wrinkles 17–27%
  • Non-invasive topical Botox alternative
  • Smooths forehead, eye area, nasolabial fold lines
  • Widely studied — published clinical efficacy data
  • Synergistic with SNAP-8 for enhanced effect
  • Reduces fine lines around eyes (crow's feet)
  • Improves skin smoothness and texture
  • Well tolerated across all skin types
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant vascular adverse events reported at standard doses
  • Generally very well tolerated
  • At >10%: temporary eyelid/brow ptosis (drooping)
  • Rare: mild redness in sensitive skin
  • No systemic absorption at cosmetic doses
Stacks With